| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers the price target from $98 to...
 
																	Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $106 t...
 
																	Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $85 to $75.
 
																	JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and lowers the price target from $90 to $75.
 
																	TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $100 to $84.
 
																	Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...
 
																	Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers the price target from $10...
 
																	RBC Capital analyst Shagun Singh maintains DexCom (NASDAQ:DXCM) with a Outperform and lowers the price target from $100 to $85.
 
																	DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margi...